Belgian biotherapeutic company Bio-Sourcing has successfully secured €12.5 million in funding from the European Innovation Council (EIC) Accelerator to enhance its innovative BioMilk platform. This funding will significantly bolster their efforts to produce cost-effective biosimilars, addressing critical healthcare challenges.
- Funding Overview: €2.5 million in grants and €10 million in equity to support biotherapeutic production.
- First Biosimilar: Adalimumab (Humira) will be the first biosimilar to enter clinical trials, expected to generate substantial revenue.
- Broader Goals: Plans to develop more biosimilars, including trastuzumab and golimumab, to enhance product offerings.
- European Manufacturing: Aims to improve Europe’s self-sufficiency in biopharmaceuticals, especially after recent global health crises.
- Future Developments: The funding will support clinical trials by 2027 and expand operations, including new facilities for goats and milk processing.
Bio-Sourcing’s innovative approach and significant funding position it to make strides in the biopharmaceutical sector, improving access to essential treatments and strengthening Europe’s manufacturing capabilities.
